Harpreet Singh, Immatics CEO

Im­mat­ics imag­ines broad­er CAR-T pipeline with an­oth­er Bris­tol My­ers pact and ad­di­tion to 2019 TCR deal

Im­mat­ics is hit­ting the gas ped­al on an­oth­er Bris­tol My­ers Squibb deal as the biotech-Big Phar­ma pair al­so lev­el up their 2019 pact, orig­i­nal­ly inked with Cel­gene.

While the Ger­man-Hous­ton biotech is still in its ear­ly-stage clin­i­cal de­vel­op­ment days, Bris­tol My­ers likes what it has seen and wants to dive deep­er in­to Im­mat­ics’ T-cell ther­a­py plat­forms. That in­cludes $60 mil­lion up­front for a new deal and an­oth­er $20 mil­lion now for an ex­pan­sion to the 2019 col­lab.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.